Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.49 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.47 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1784527 | 0.90 | TRPV1 (0.49) | TRPV1MALT1ALDH1A1 | |
| SCHEMBL7913643 | 0.87 | MALT1 (0.45) | TRPV1MALT1ALDH1A1 | |
| SCHEMBL616219 | 0.82 | TRPV1 (0.41) | TRPV1 | |
| SCHEMBL1783734 | 0.79 | TRPV1 (0.44) | TRPV1ALDH1A1 | |
| SCHEMBL616240 | 0.79 | JAK2 (0.43) | TRPV1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1781429 | 0.78 | TRPV1 (0.44) | TRPV1ALDH1A1 | |
| SCHEMBL616586 | 0.78 | TRPV1 (0.41) | TRPV1MALT1PANK3CA12CA1 | |
| SCHEMBL1782304 | 0.78 | TRPV1 (0.47) | TRPV1MALT1ALDH1A1 | |
| SCHEMBL614007 | 0.78 | JAK2 (0.45) | TRPV1ALDH1A1KDM4E | |
| SCHEMBL615155 | 0.77 | MALT1 (0.43) | TRPV1MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303542-A1 | SUBSTITUTED PYRAZINAMIDE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303542-A1 | SUBSTITUTED PYRAZINAMIDE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-11-14 | — | — | US | disclosed |
| US-20120183579-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183579-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2350004-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corp. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2011-05-19 | — | — | US | disclosed |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2011-05-19 | — | — | US | disclosed |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2011-05-19 | — | — | US | disclosed |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-05-20 | — | — | US | disclosed |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-05-20 | — | — | US | disclosed |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-05-20 | — | — | US | disclosed |
| WO-2010039236-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303542-A1 | SUBSTITUTED PYRAZINAMIDE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | NLRP3, NLRP1, CXCL8 | TRPV1 111/4885MALT1 197/4885PANK3 412/4885 |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | TRPV1 92/4885MALT1 138/4885PANK3 1057/4885 |
| US-20120183579-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | TRPV1 92/4885MALT1 138/4885PANK3 1057/4885 |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | TRPV1 92/4885MALT1 138/4885PANK3 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.